Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

NCT00141323 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

8556

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis

Interventions

DRUG: lasofoxifene
OTHER: placebo
DRUG: lasofoxifene

Sponsor

Ligand Pharmaceuticals